# Acalabrutinib Real World Italian obSErvational Study -ARISE

> **NCT06205498** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 151 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** acalabrutinib

## Key facts

- **NCT ID:** NCT06205498
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-08
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06205498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06205498, "Acalabrutinib Real World Italian obSErvational Study -ARISE". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06205498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*